Neuro-Bio Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.7M
- Investors
-
4
Neuro-Bio General Information
Description
Developer of novel therapeutics designed to provide treatment of neurodegenerative disorders. The company's therapeutics are engaged in the discovery and development of oral drugs along with a biomarker for the identification of novel amino acid bioactive peptides, enabling physicians to have an effective approach to treating neurodegenerative and related diseases.
Contact Information
Website
www.neuro-bio.comCorporate Office
- Building F5, Culham Campus Abingdon
- Culham Science Centre, Oxfordshire
- Abingdon OX14 3DB
- England, United Kingdom
Corporate Office
- Building F5, Culham Campus Abingdon
- Culham Science Centre, Oxfordshire
- Abingdon OX14 3DB
- England, United Kingdom
Neuro-Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 07-Oct-2024 | $5.7M | Completed | Pre-Clinical Trials | ||
| 7. Later Stage VC (Series C) | Cancelled | Pre-Clinical Trials | ||||
| 6. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 5. Later Stage VC | 18-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series B) | 27-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 15-Mar-2017 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 31-Aug-2016 | $1.67M | $2.69M | Completed | Pre-Clinical Trials | |
| 1. Angel (individual) | 23-Dec-2013 | $1.02M | $1.02M | Completed | Startup |
Neuro-Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C-1 Preferred | ||||||||
| Ordinary | ||||||||
| C-1 Preferred | ||||||||
| C-1 Preferred | ||||||||
| C-1 Preferred | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| B-2 Prefered | 9,439 | $0.001323 | $34.06 | $34.06 | 1x | $34.06 | 2.68% | |
| Ordinary | 15,579 | $0.001323 | $34.06 | $34.06 | 1x | $34.06 | 4.43% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Neuro-Bio Comparisons
Industry
Financing
Details
Neuro-Bio Competitors (73)
One of Neuro-Bio’s 73 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Neuro-Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neuro-Bio Patents
Neuro-Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202308779-D0 | Aptamer | Inactive | 13-Jun-2023 | ||
| WO-2024256815-A1 | Aptamer | Inactive | 13-Jun-2023 | ||
| GB-202308799-D0 | Neurodegenerative disease | Inactive | 13-Jun-2023 | ||
| WO-2024256817-A1 | Neurodegenerative disease biomarkers | Inactive | 13-Jun-2023 | ||
| WO-2024224088-A1 | T14 antagonists for use in the treatment of rapamycin-sensitive conditions | Inactive | 26-Apr-2023 | A61K38/465 |
Neuro-Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuro-Bio Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jaguar Finance | Venture Capital | Minority | ||
| P&S Yates Holdings Pty Ltd | Corporation | Minority | ||
| Stewart Atkinson Ventures | Venture Capital | Minority | ||
| Kairos Ventures | Venture Capital | Minority |
Neuro-Bio FAQs
-
When was Neuro-Bio founded?
Neuro-Bio was founded in 2013.
-
Where is Neuro-Bio headquartered?
Neuro-Bio is headquartered in Abingdon, United Kingdom.
-
What is the size of Neuro-Bio?
Neuro-Bio has 25 total employees.
-
What industry is Neuro-Bio in?
Neuro-Bio’s primary industry is Drug Discovery.
-
Is Neuro-Bio a private or public company?
Neuro-Bio is a Private company.
-
What is the current valuation of Neuro-Bio?
The current valuation of Neuro-Bio is .
-
What is Neuro-Bio’s current revenue?
The current revenue for Neuro-Bio is .
-
How much funding has Neuro-Bio raised over time?
Neuro-Bio has raised $15.3M.
-
Who are Neuro-Bio’s investors?
Jaguar Finance, P&S Yates Holdings Pty Ltd, Stewart Atkinson Ventures, and Kairos Ventures have invested in Neuro-Bio.
-
Who are Neuro-Bio’s competitors?
Aqualung Therapeutics, Alzheon, Mestag Therapeutics, Enterprise Therapeutics, and Rein Therapeutics are some of the 73 competitors of Neuro-Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
